Iterum Therapeutics (ITRM)
(Delayed Data from NSDQ)
$1.58 USD
-0.06 (-3.66%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $1.56 -0.02 (-1.27%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
Iterum Therapeutics PLC [ITRM]
Reports for Purchase
Showing records 21 - 40 ( 72 total )
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
3Q Recap; Type B Meeting With FDA Around YE21; New Phase 3 uUTI Trial Start Expected in 1H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
IDWeek 2021: Poster Presentation Highlights Within Our Antibiotics Coverage Space
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Type A Meeting Offers Path Forward for Sulopenem via New Phase 3 Study; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
2Q21 Recap: Type A Meeting With FDA in Coming Weeks to Determine Sulopenem''s Future; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
CRL Requests a New Sulopenem Trial; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
FDA Flags Deficiencies in Sulopenum NDA; Approval on July 25 PDUFA at Risk; Maintain Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Avoiding the Distracting Whipsaw of Agency Communications, We Remain Focused on July 25 PDUFA; 1Q Recap; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
4Q Recap: A Clear Line of Sight to a Significant Opportunity in uUTI; Upgrading to Buy, $2.50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Sulopenem NDA for uUTI Accepted With July 25 PDUFA Date; Awaiting Commercial Plan to Solidify; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E